

Ascendis Pharma A/S

Week 104 Results From the Pivotal ApproaCH Trial Open-Label Extension

Presented at ACMG on March 13, 2026

Cautionary Note on Forward-Looking Statements


This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this presentation, such as statements regarding our products and prospective product candidates; revenue and growth expectations; clinical trial results; the expected timing of future clinical trial results, regulatory filings and feedback from regulatory authorities; the scope, progress, results and costs of developing our product candidates or any other future product candidates; timing and likelihood of success; patient enrollment; timing and expansion of commercial launches, pipelines, and investments; plans and objectives of management for future operations and commercialization and manufacturing activities; and future results of current and/or anticipated products and product candidates are forward-looking statements. These forward-looking statements are based on our current expectations and beliefs, as well as assumptions concerning future events. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the results discussed in the forward-looking statements. These risks, uncertainties and other factors include, but are not limited to: risks related to regulatory review and approval, including the possibility that continued approval under the FDA's Accelerated Approval Program may be contingent upon verification and description of clinical benefit in confirmatory trials, and the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, or failure to obtain or maintain approval in the United States, European Union, or other jurisdictions; clinical development risks, including the risk that results from ongoing or future clinical trials may not confirm earlier data or support further development; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions, health technology assessments, and the willingness of patients and physicians to adopt YUVIWEL over existing therapies; competitive developments, including the introduction of new or improved therapies by other companies; and intellectual property protection, freedom-to-operate, and litigation risks. These risks, uncertainties and other factors are more fully described in our reports filed with or submitted to the Securities and Exchange Commission ("SEC"), including our most recent Annual Report on Form 20-F filed with the SEC on February 11, 2026, particularly in the sections titled "Risk Factors" and "Operating and Financial Review and Prospects," and other future reports filed with, or submitted to, the SEC. In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. Any forward-looking statement made by us in this presentation speaks only as of the date of this presentation and represents our estimates and assumptions only as of the date of this presentation. Except as required by law, we assume no obligation to update these statements publicly, whether as a result of new information, future events, changed circumstances or otherwise after the date of this presentation.

This presentation concerns Ascendis Pharma approved products as well as Ascendis Pharma investigational product candidates that are or have been under clinical investigation and which have not yet been approved for marketing by the U.S. Food and Drug Administration, European Medicines Agency or other foreign regulatory authorities. These investigational product candidates are currently limited by law to investigational use, and no representations are made as to their safety or effectiveness for the purposes for which they are being investigated. This presentation is for investor communications only. Not for use in product promotion.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

This presentation contains trademarks, service marks, trade names and copyrights of the company and other companies, which are the property of their respective owners. The use or display of third parties' trademarks, service marks, trade names or products in this presentation is not intended to, and does not imply, a relationship with the company, or an endorsement or sponsorship by the company.

Navepegritide (TransCon[®] CNP)




- Navepegritide is a prodrug of CNP administered once weekly and designed to provide continuous exposure to active CNP (amino acid sequence identical to endogenous CNP [89-126])
- Active CNP released from navepegritide binds to NPR-B throughout the body to counteract the constitutively active FGFR3 signaling in achondroplasia
- Navepegritide (YUVIWEL[®]) is approved by the FDA to increase linear growth in children 2 years and older with achondroplasia with open epiphyses

CNP = C-type natriuretic peptide; FDA = Food and Drug Administration; FGFR3 = fibroblast growth factor receptor 3; NPR-B = natriuretic peptide receptor B
Breinholt VM, et al. *J Pharmacol Exp Ther* 2019;370(3):459-471.


ApproaCH Trial Design

Randomization

Treatment-naïve children with achondroplasia (aged 2 to 11 years)



Double-Blind Period



Open-Label Extension (OLE)



Week 52

Week 104

Primary Endpoint: Annualized growth velocity (**AGV**) at Week 52

Key Secondary Endpoints: Change from baseline in achondroplasia-specific and CDC-based **height Z-scores**

Safety and Tolerability Assessments: Treatment emergent adverse events (TEAEs) and bone age

N = number of children that received at least one dose of investigational medicinal product
CDC = Centers for Disease Control and Prevention


ApproaCH Primary Endpoint: Annualized Growth Velocity (AGV) at Week 52

JAMA Pediatrics

Original Investigation

Once-Weekly Navepegritide in Children With Achondroplasia
The APPROACH Randomized Clinical Trial


Savarirayan R, et al. *JAMA Pediatr* 2026;180(1):18-25.
doi:10.1001/jamapediatrics.2025.4771



Results from the double-blind period demonstrated superiority of once-weekly navepegritide over placebo for AGV at Week 52

Note: Box-and-whisker plots derived using observed data at Week 52 and display the 75th and 25th percentile (box edges), IQR (colored area), median (midline), and minimum and maximum observed values; labeled circles represent least squares mean values. Missing height data at Week 52 for 2 participants in the navepegritide group were imputed using the multiple imputation method. AGV = annualized growth velocity; CI = confidence interval; IQR = interquartile range; LS = least squares

Approach Trial Disposition



N = number of participants that received at least one dose of investigational medicinal product; n=number of participants that received at least one dose and completed the respective trial period. In the navepegritide group, 2 participants withdrew in the double-blind period (both were withdrawn by parent/guardian), and 2 participants discontinued treatment during the OLE (1 was lost to follow-up; 1 was withdrawn by parent/guardian). OLE = Open-Label Extension


ApproaCH Trial Participant Characteristics

Demographics and clinical characteristics at the start of the OLE (Week 52)	navepegritide/navepegritide (N=55)	placebo/navepegritide (N=27)	Total population (N=82)
Age (years), mean (SD) [min, max]	6.6 (2.7) [3.0, 13.0]	7.0 (2.8) [3.1, 13.0]	6.8 (2.7) [3.0, 13.0]
Sex, Male, n (%)	29 (52.7)	14 (51.9)	43 (52.4)
Height (cm), mean (SD)	94.7 (13.0)	93.3 (10.8)	94.3 (12.3)
Achondroplasia-specific height Z-score, mean (SD)	0.44 (0.97)	-0.11 (0.73)	0.26 (0.93)
CDC-based height Z-score, mean (SD)	-4.81 (1.03)	-5.35 (0.87)	-4.99 (1.01)
AGV (cm/year), observed mean (SD)	5.95 (0.99)	4.29 (1.21)	5.40 (1.32)

At the start of the Open-Label Extension, AGV and height Z-scores reflected the positive effect of navepegritide on growth outcomes in the double-blind period

N = number of participants that received at least one dose of investigational medicinal product
 AGV = annualized growth velocity; CDC = Centers for Disease Control and Prevention; OLE = Open-Label Extension

Annualized Growth Velocity (AGV) through Week 104




Children continuing navepegritide in the Open-Label Extension maintained AGV through 104 weeks

Children who switched from placebo to navepegritide at Week 52 had increased AGV at Week 104, comparable to navepegritide-related gains observed in the double-blind period


Note: Data shown are observed mean (±SE) Annualized Growth Velocity (AGV).

Change in ACH-specific Height Z-score




In the Open-Label Extension, ACH-specific height Z-score increased with navepegritide treatment, consistent with navepegritide-related improvements seen in the double-blind period

Change in CDC-based Height Z-score



CDC-based height Z-score improved with navepegritide treatment in the double-blind period, and continued to increase with navepegritide treatment in the Open-Label Extension

Change in Upper-to-Lower Body Segment Ratio



In the Open-Label Extension, numeric improvement was observed in both groups, indicating promotion of proportional growth with navepegritide treatment

Safety and Tolerability Through 104 Weeks

	Total navepegritide-treated population (N=84)
Treatment exposure	137.1 person-years
Events through Week 104	n (%)
Any Treatment-Emergent Adverse Event (AE)	76 (90.5)
Grade 1 (Mild)	74 (88.1)
Grade 2 (Moderate)	39 (46.4)
Grade 3 (Severe)	7 (8.3)
Grade 4 (Life-threatening) or 5 (Death)	0 (0.0)
Treatment-related AEs	19 (22.6)
Injection Site Reaction (ISR)	17 (20.2)
Serious Adverse Events (SAE)	3 (3.6)
Treatment-related SAEs	0 (0.0)
Symptomatic hypotension	0 (0.0)

- The overall rate of ISRs was low, and all events were mild
 - 0.35 ISRs per person-year of exposure is equivalent to approx. 1 ISR for every 3 years of treatment
- No symptomatic hypotension occurred through up to 104 weeks of navepegritide treatment

Most adverse events in navepegritide-treated children were mild or moderate, with none leading to treatment discontinuation or withdrawal from the trial

n = number of participants with observation.

Bone Health During the Open-Label Extension

Ratio of Bone Age to Chronological Age	navepegritide/navepegritide (N=55)		placebo/navepegritide (N=27)	
	N	Mean (SE)	n	Mean (SE)
Week 52 (start of Open-Label Extension)	55	0.84 (0.02)	27	0.85 (0.03)
Week 104	53	0.91 (0.02)	27	0.92 (0.02)
Change from Week 52 to Week 104	53	0.07 (0.02)	27	0.07 (0.02)

- There were 2 fractures reported in the Open-Label Extension
 - Both fractures were associated with trauma, and neither was considered by the investigator to be related to study treatment

**Bone maturation did not accelerate with navepegritide treatment,
and no fractures related to treatment were observed in the Open-Label Extension**

Note: Reported fractures were a clavicle fracture in a 2.1-year-old male participant, and a radius fracture in a 5.7-year-old female participant.

Key Takeaways

During the Open-Label Extension phase of the ApproaCH Trial:

- Children continuing treatment with navepegritide maintained the elevated AGV observed during the double-blind period through Week 104
- Children who switched from placebo to navepegritide at Week 52 exhibited increased AGV at Week 104, comparable to the navepegritide-related improvements seen in the double-blind period
- In both groups, achondroplasia-specific and CDC-based height Z-scores improved with navepegritide treatment; gains were consistent with those observed with navepegritide in the double-blind period
- Improvement in upper-to-lower body segment ratio with navepegritide treatment indicates promotion of proportional growth during the Open-Label Extension

Results from the ApproaCH Trial support the efficacy and safety of navepegritide through up to 104 weeks of treatment

AGV = annualized growth velocity; CDC = Centers for Disease Control and Prevention

Thank you

Investor Relations
Ascendis Pharma

ascendispharma.com